If you think microbes are culprit in dementia, Alzheimer’s Germ Quest will pay $1 million for convincing evidence. CEO Leslie Norins, MD, PhD, who is fronting the money, says the three-year-long contest is open to researchers from around the globe.
Even if a high-salt diet doesn’t lead to blood pressure problems, it could still be damaging blood vessels in the brain, potentially having an impact on cognition, a mouse study in Nature Neuroscience found. (Los Angeles Times)
The VA said it won’t do research on medical marijuana for post-traumatic stress disorder or chronic pain, even as veterans groups are pushing for use of the drug as an alternative to opioids and antidepressants. VA Secretary David Shulkin cited federal law as the barrier. (Washington Post)
Roche’s ocrelizumab (Ocrevus) has been cleared as a multiple sclerosis treatment in Europe. The monoclonal antibody was approved to treat both relapsing and primary progressive MS in the U.S. in March 2017, and brought in $1 billion in sales in its first nine months on the market. (Endpoints News)
Scientific American takes a deeper dive into antisense therapies targeting mutant HTT as a treatment for Huntington’s disease.
Find out how neurologists are addressing the need for diversity in their specialty. (Neurology Today)